FDA Approves Oral Wegovy, the First Daily GLP-1 Pill
NewBeauty Facebook Pinterest Instagram Youtube find a doctor Face Adult Acne Antioxidants Anti-Aging Celebrity Chronic Skin Conditions Eye Hydration Hyperpigmentation Makeup View All Eyebrows Eye Color Foundation Fragrance Lip Color Makeovers Male Skin Care Peels Pre-Event Prep Sensitive Skin Skin Care Skin Health Smile Sun Care Treatments Fillers Microneedling Post-Procedure Skin Care Neurotoxins Regenerative Aesthetics Skin Lifting Body Body Sculpting Breasts Butts Cellulite Hair Removal Hands + Nails Legs Pregnancy Find a Doctor Hair Bond Repair Celebrity Dry Hair Frizzy Hair Gray Hair Hair Color Hair Growth Hair Repair Scalp Health Styling + Tips Awards NB100 Awards 15th Annual Beauty Awards 2025 NewBeauty Readers’ Choice Awards Shopping Gift Guides Product Reviews NewBeauty Storefront Wellness Fitness GLP-1s Health Menopause About Us TESTTUBE Search for: Search HomeWellnessGLP-1s FDA Approves Oral Wegovy, the First Daily GLP-1 Pill Novo Nordisk marks a turning point in obesity care. Tatiana Bido Published: Dec 23, 2025 Image / Novo Nordisk In This Article Featured ExpertsHow Oral Wegovy Changes the GLP-1 LandscapeWhich Patients May Benefit MostThe Science Behind Oral Wegovy Weight-loss treatment just became needle-free. The Food and Drug Administration (FDA) has approved an oral version of Wegovy from Novo Nordisk, making it the first GLP-1 pill cleared for obesity treatment. Until now, highly effective GLP-1 medications have only been available as injections. The newly approved pill offers a once-daily alternative with results comparable to the injectable version. In late-stage trials, patients taking the highest dose lost about 14 percent of their body weight, similar to injectable Wegovy. Like its injectable counterpart, the pill is also approved to reduce cardiovascular risk. Here’s what patients should know as daily pill options enter the GLP-1 conversation.